# Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant

> **NCT07430059** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Vivani Medical, Inc** · enrollment: 20 (estimated)

## Conditions studied

- Obesity & Overweight

## Interventions

- **COMBINATION_PRODUCT:** Semaglutide Implant (NPM-139)
- **DRUG:** Semaglutide (Wegovy) weekly injection

## Key facts

- **NCT ID:** NCT07430059
- **Lead sponsor:** Vivani Medical, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2026-08
- **Final completion:** 2026-09
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07430059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07430059, "Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07430059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*